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This publication introduces a series of eight other publications describing the non-clinical assessment
and initial clinical study of a candidate modiﬁed risk tobacco product (MRTP) e the Tobacco Heating
System 2.2 (THS2.2). This paper presents background information on tobacco harm reduction, to com-
plement the approaches aimed at increasing smoking cessation and reducing smoking initiation to
reduce the morbidity and mortality caused by cigarette smoking. THS2.2 heats tobacco without com-
bustion, and the resulting formation of harmful and potentially harmful constituents (HPHC) is greatly
reduced compared with cigarette smoke. Assessment of the THS2.2 aerosol in vitro and in vivo reveals
reduced toxicity and no new hazards. Additional mechanistic endpoints, measured as part of in vivo
studies, conﬁrmed reduced impact on smoking-related disease networks. The clinical study conﬁrmed
the reduced exposure to HPHCs in smokers switching to THS2.2, and the associated transcriptomic study
conﬁrmed the utility of a gene expression signature, consisting of only 11 genes tested in the blood
transcriptome of subjects enrolled in the clinical study, as a complementary measure of exposure
response. The potential of THS2.2 as an MRTP is demonstrated by the assessment and additional pub-
lications cited in this series.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. General
The U.S. Family Smoking Prevention and Tobacco Control Act
deﬁnes a Modiﬁed Risk Tobacco Product (MRTP) as any tobacco
product that is sold or distributed for use to reduce harm or the riskuct; THS2.2, Tobacco Heating
System version 2.2 menthol
stituents; PMI, Philip Morris
d Tobacco Control Act; FDA,
o Products; CDER, Center for
garette; CVD, Cardiovascular
NPA, Network perturbation
nization for Economic Coop-
impact model; HCI, Health
entucky Reference Cigarette;
d reference cigarettes; SA,
ith).
anies.
Inc. This is an open access article uof tobacco related disease associated with commercially marketed
tobacco products (Family Smoking Prevention and Tobacco Control
Act). This publication is part of a series of nine publications
describing the nonclinical and part of the clinical assessment of a
candidate MRTP, THS2.2 regular and a mentholated version
(THS2.2M). The series of publications provides part of the overall
scientiﬁc program to assess the potential for THS2.2 to be a reduced
risk product. This ﬁrst publication in this series describes THS2.2
and the assessment program for MRTPs. This is followed by six
publications that describe the nonclinical assessment of THS2.2
regular and THS2.2M (Kogel et al., 2016; Oviedo et al., 2016;
Schaller et al., 2016a; Schaller et al., 2016b; Sewer et al., 2016;
Wong et al., 2016). The eighth publication in the series describes a
clinical study to assess whether the reduced formation of Harmful
and Potentially Harmful Constituents (HPHC) for THS2.2 regular
also leads to reduced exposure to HPHCs when the product is used
in a clinical setting (Haziza, 2016). A ﬁnal publication utilizes data
gathered from the reduced exposure clinical study on THS2.2 reg-
ular to determine if a systems pharmacology approach can identify
exposure response markers in peripheral blood of smokers
switching to THS2.2 (Martin et al., 2016).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The Harm Reduction Equation. Harm reduction at the population level is the
result of the availability of a scientiﬁcally substantiated reduced-risk product that is an
acceptable alternative to adult smokers and is not likely to attract non-smokers.
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Cigarette smoking is one of the leading causes of preventable
death both in the United States and globally. For many decades, the
foundational principles of reducing this harm have been focused on
preventing smoking initiation and promoting smoking cessation. In
recent years, a third opportunity to reduce the harm from com-
busted tobacco products has emerged, based on switching con-
sumers to less harmful products that have signiﬁcantly reduced
levels of toxic and harmful compounds. The United States Surgeon
General (US Department of Health and Human Services (2010))
concluded that ‘Inhaling the complex chemical mixture of combustion
compounds in tobacco smoke causes adverse health outcomes,
particularly cancer and cardiovascular and pulmonary diseases,
through mechanisms that include DNA damage, inﬂammation and
oxidative stress.’ It has long been known that the best way for
smokers to reduce the adverse health consequences of smoking is
to quit. However, though many smokers are interested in and
attempt to quit, it can be very difﬁcult to quit smoking cigarettes
and hence the rates of long-term smoking cessation remain low. For
example, according to the United States Surgeon General (US
Department of Health and Human Services (2010)) although
about 45% of smokers quit for a day, only approximately 5% succeed
in achieving long-term abstinence for one year or longer.
As outlined by the U.K. Royal College of Physicians (Royal College
of Physicians (2016)), ‘Smoking is completely preventable, yet, more
than half a century after the health harm of smoking ﬁrst became
widely known, almost 1 billion people worldwide still smoke. They do
so primarily because they are addicted to the nicotine in tobacco
smoke and, as this addiction can be extremely difﬁcult to overcome,
many will continue to smoke until they die.’
Referring to an earlier report (Royal College of Physicians
(2007)) that promoted the principle of harm reduction in nicotine
addiction, the Tobacco Advisory Group of the U.K. Royal College of
Physicians (Royal College of Physicians (2016)) stated that ’as most
of the harm caused by smoking arises not from nicotine but from other
components of tobacco smoke, the health and life expectancy of to-
day's smokers could be radically improved by encouraging as many as
possible to switch to a smoke-free source of nicotine. While recog-
nizing the primacy of complete cessation of all tobacco and nicotine
use as the ultimate goal to prevent harm from smoking, the report
argued that promoting widespread substitution of cigarettes and other
tobacco combustion products would, for smokers who made the
change, achieve much the same thing. Harm reduction, as a comple-
ment to conventional tobacco control policies, could therefore offer a
means to prevent millions of deaths among tobacco smokers in the UK
alone.’
As noted by McNeil (McNeil, 2012) ‘Since nicotine itself is not a
highly hazardous drug, encouraging smokers to obtain nicotine from
sources that do not involve tobacco combustion is a potential means to
reduce the morbidity and mortality they sustain, without the need to
overcome their addiction to nicotine.’
The harm reduction approach can be used to complement the
existing strategies of reducing smoking related harm (i.e., pre-
venting initiation and promoting cessation of smoking), to provide
smokers with novel tobacco or nicotine containing products that
are substantially less toxic than cigarettes. However, the potential
public health beneﬁt of such an approach will only be achieved if
these novel nicotine products are scientiﬁcally substantiated to
reduce risk and are acceptable alternatives that allow smokers to
switch to the reduced-risk products.
Philip Morris International (PMI) is developing a portfolio of
such novel nicotine products to address a wide range of adult
smoker preferences where each product type is designed to
signiﬁcantly reduce or eliminate the formation of HPHCs in theinhaled aerosol while preserving as much as possible the taste,
sensory experience, nicotine delivery proﬁle and ritual character-
istics of cigarettes.
The novel nicotine product described in this series of papers is a
‘heat-not-burn’ tobacco product, which heats tobacco at a temper-
ature below that required to initiate combustion. Different classes
of tobacco constituents decompose at different temperatures,
releasing chemical compounds into the aerosol. Heating at much
lower temperatures than those found at the tip of a burning ciga-
rette generates fewer and lower levels of HPHCs. The resulting
aerosol contains nicotine but has signiﬁcantly reduced levels of
HPHCs compared with cigarette smoke.
The development of heat-not-burn tobacco products is not new
and earlier efforts to develop such products (notably Premier and
Eclipse products from R.J. Reynolds and Accord from Philip Morris)
have been reviewed (Baker, 2006). Baker concluded that consumer
acceptance of these products was low primarily because of sensory
and usability issues, explaining their lack of commercial success.
Consumer acceptance of reduced-risk products is crucially impor-
tant if they are to be used in place of cigarettes and realize the
potential to reduce risk for the individual smoker and for harm
reduction at the population level (Fig. 1).
The studies presented in this series of papers form part of an
assessment strategy to characterize a potentially reduced-risk
product that generates an inhalable aerosol by heating tobacco
instead of burning it. A description of this Tobacco Heating System
(THS) version 2.2 is provided below, followed by an overview of our
MRTP assessment strategy.2. Product characteristics of THS2.2
THS 2.2 is a novel tobacco product type. It has three distinct
components that perform different functions (Fig. 2): (i) a tobacco
stick - a novel patent-pending tobacco product with processed to-
bacco made from tobacco powder, (ii) a holder into which the to-
bacco stick is inserted and which heats the tobacco material by
means of an electronically controlled heating blade, and (iii) a
charger that is used to recharge the holder after each use.
The THS2.2 product differs from a cigarette in signiﬁcant ways.
First, the tobacco stick does not contain tobacco cut-ﬁller (tobacco
leaf cut in small pieces found in cigarettes). Instead, the tobacco is
ground and reconstituted into sheets (termed cast-leaf) following
the addition of water, glycerin, guar gum and cellulose ﬁbers.
Second, the tobacco stick (Fig. 3) contains much smaller amounts of
tobacco compared with a cigarette. The weight of the tobacco plug
in the tobacco stick is approximately 320 mg compared with the
550e700 mg cut-ﬁller found in conventional cigarettes. The
reconstituted tobacco cast-leaf is fashioned into a small plug
through a proprietary process known as ‘crimping’. Third, unlike a
cigarette, the tobacco stick contains two unique and independent
ﬁlters: (i) a polymer-ﬁlm ﬁlter to cool the aerosol and (ii) a low-
density cellulose acetate mouthpiece ﬁlter to mimic the sensory
aspects of a cigarette. Furthermore, a hollow acetate tube separates
the tobacco plug and the polymer-ﬁlm ﬁlter.
To operate the THS2.2 product, the user inserts a tobacco stick
Fig. 2. The three components of the THS 2.2 product.
Fig. 3. Cross-sectional view of the tobacco stick.
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initiates the heating of the tobacco via the heating blade inserted
into the tobacco plug. The tobacco neither ignites nor burns. The
electronically controlled heating, in combination with the uniquely
processed tobacco, prevents combustion from occurring. Heat is
supplied to the tobacco stick for a ﬁxed period of approximately
6 min and allows up to 14 puffs to be taken during that time. The
temperature of the heating blade is carefully controlled and the
energy supply to the blade is cut if its operating temperature ex-
ceeds 350 C.
When a cigarette is lit, the combination of tobacco (fuel) and
oxygen in the air generates a self-sustaining combustion process
that consumes the tobacco. During the period between puffs, the
tobacco smolders at temperatures ranging from 600 to 800 C in
the center of the combustion zone. During a puff, the temperature
increases to more than 900 C at the periphery of the combustion
zone (Baker, 1975). The combustion of tobacco results in formation
of heat, smoke and ash. The smoke formed is a complex aerosol
mixture estimated to contain more than 8000 compounds
(Rodgman and Perfetti, 2013).
In contrast, the operating temperature of the THS 2.2 product is
substantially lower than that required to cause ignition and com-
bustion of tobacco and the temperature measured in the tobacco
does not exceed 300 C. When a puff is taken from the tobacco stick
the tobacco temperature drops as ambient air is drawn through the
tobacco stick. Since combustion does not occur, the structural
integrity of the tobacco stick is retained after use. The tobacco is not
consumed as in a cigarette and no ash is formed. The experimental
conﬁrmation that no combustion takes place during use of the THS
2.2 product as intended have been presented recently (Cozzani
et al., 2016.) (and a separate publication is in preparation). This
absence of combustion, because of controlled heating, is designed
to signiﬁcantly reduce formation of HPHCs by the THS2.2 product
compared with cigarettes. This is conﬁrmed by the chemicalanalysis of the inhalable aerosol delivered by the THS2.2 product in
comparison with the smoke of a 3R4F reference cigarette (Schaller
et al., 2016a).
3. The MRTP assessment strategy
In 2009, the United States Congress passed the Family Smoking
Prevention and Tobacco Control Act (FSPTCA) granting the United
States Food and Drug Administration (FDA) authority to regulate
tobacco products, which, among other things, established the ﬁrst
regulatory procedure for reviewing an application and authorizing
to market a reduced-risk tobacco product, (referred to in the U.S.
law as a ‘Modiﬁed Risk Tobacco Product,’ orMRTP) (Family Smoking
Prevention and Tobacco Control Act). An MRTP is deﬁned by the
FSPTCA as ‘any tobacco product that is sold or distributed for use toreduce harm or the risk of tobacco related disease associated with
commercially marketed tobacco products.’ The FDA stated in its
MRTP Draft Guidance document (Food and Drug Administration,
2012) that the MRTP provisions of the FSPTCA ‘may be valuable
tools in the effort to promote public health by reducing the morbidity
and mortality associated with tobacco use, particularly if companies
take advantage of these provisions by making bold, innovative product
changes … ’
The FSPTCA provides for the authorization of an MRTP when
reduced exposure or reduced risk has been substantiated by
applying a rigorous scientiﬁc assessment. Different levels of evi-
dence are required for these respective authorizations, with ability
for communicating product attributes with a reduced risk versus a
modiﬁed exposure order. The FSPTCA requires applicants to
demonstrate that the product, as actually used, will (i) signiﬁcantly
reduce harm and the risk of tobacco-related disease to individual
tobacco users, and (ii) beneﬁt the health of the population as a
whole, taking into account both the users of tobacco products and
persons who do not currently use tobacco products.
In contrast, the approach adopted by the European Union To-
bacco Products Directive (European Parliament and Council
Directive 2014/40/EU, 2014) is less detailed in its requirements
than the approach adopted by FDA. The EU requires the submission
of available product-speciﬁc studies and information in its notiﬁ-
cation process, but currently has no mechanism to authorize con-
sumer information relating to reduced exposure or reduced risk.
Since the European Union Tobacco Products Directive (European
Parliament and Council Directive 2014/40/EU, 2014) was imple-
mented in May 2016, manufacturers and importers are required to
submit a notiﬁcation to the competent authorities of Member
States for any novel tobacco product they intend to market. A novel
tobacco product is deﬁned as one that does not fall into any of the
existing categories of tobacco products and is placed on the market
after 19 May 2014. The notiﬁcation should include:
Fig. 4. Risk framework for MRTP assessment. Conceptual depiction of the cumulated
risk of smoking and the effect of cessation over time. These represent the two
boundaries for the assessment of an MRTP: 1) comparing switching to an MRTP with
continued smoking and 2) benchmarking switching against smoking cessation (gold
standard). Note that the straight lines used in this ﬁgure are for illustration purposes
only as the accumulation of disease risk and the reduction upon cessation and
switching to an MRTP follow different trajectories for speciﬁc diseases.
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attractiveness of the novel tobacco product, in particular as
regards its ingredients and emissions,
b) Available studies, executive summaries thereof and market
research on the preferences of various consumer groups,
including young people and current smokers,
c) Other available and relevant information, including a risk/
beneﬁt analysis of the product, its expected effects on cessation
of tobacco consumption, its expected effects on initiation of
tobacco consumption and predicted consumer perception.
The reduced exposure evaluation of an early heat-not-burn
product (electrically heated cigarette smoking system e ‘Heatbar’)
developed and assessed by PMI prior to the enactment of the
FSPTCA, has been described previously (Schorp et al., 2012); it was
recognized that ‘a comprehensive assessment of reduced exposure is
necessary, but is not sufﬁcient for determining a modiﬁed tobacco
product's potential to reduce risk.’
The approaches to assess the risk of MRTPs relative to cigarette
products have been described by the Institute of Medicine (Institute
of Medicine (2012)) and reviewed recently (Berman et al., 2015). In
this context, we have developed an assessment strategy designed
to meet the more stringent requirements of the FDA's draft MRTP
guidance that would also be applicable for the assessment of
candidate MRTPs to be marketed in other jurisdictions.
The draft guidance from the FDA Center for Tobacco Products
(CTP) indicates that the basis for authorizing an MRTP is somewhat
different to the criteria applied by the Center for Drug Evaluation
and Research (CDER) to the approval of a drug product. In the case
of a drug, the general approach is to focus on a single or a very
limited number of well-substantiated clinically relevant endpoints
as indicators of a therapeutic effect. In the case of an MRTP, how-
ever, where product-speciﬁc epidemiological evidence is not
available and clinical experience is limited, a different approach to
product assessment has to be developed. It is well understood that
the relative risk of smoking is not deﬁned by a single endpoint or
even endpoints reﬂective of a single disease or biological mecha-
nism. Therefore, the evaluation of relative risk must take into ac-
count the complex nature of the whole organism and the many
biological mechanisms that are affected by smoking. The approach
to assess a candidate MRTP therefore needs to address this
complexity by exploring a broad array of disease indicators to
demonstrate that the use of the candidate MRTP has a reduced
impact e compared with cigarettes e on mechanisms leading to
tobacco-related diseases. This approach needs to be based on the
best available science short of long-term epidemiological studies,
which can be initiated once the product is on the market and under
actual use conditions. The CTP has acknowledged this limitation in
the draft guidance (Family Smoking Prevention and Tobacco
Control Act; Food and Drug Administration, 2012). We under-
stand this to mean that initial authorization of an MRTP will be
based on non-clinical and clinical data which will be supplemented
with post-marketing data. Evaluation of the relative level of risk of
long-term use of an MRTP can begin once the product is authorized
based on a weight-of-evidence approach conﬁrming the potential
for risk reduction relative to cigarette use.
3.1. The MRTP assessment framework
In this context, we have formulated a framework that utilizes
what is known about combustible cigarette (CC) smoking and in-
corporates both epidemiological and mechanistic evidence to
deﬁne our assessment approach. Epidemiological studies inform
about the causal relationship between CC smoking and disease risk,
as well as the beneﬁts of smoking cessation. Ongoing exposure tocigarette smoke leads to both a time- and dose-dependent increase
in the risk of developing smoking-related diseases, such as car-
diovascular disease (CVD), chronic obstructive pulmonary disease
(COPD), and lung cancer. The accrued health risk over time can be
reduced gradually by smoking cessation. The cause-and-effect re-
lationships between smoking and these diseases are based on
sound epidemiological evidence, conceptually depicted in Fig. 4
(red and green lines). The United States Institute of Medicine
(Institute of Medicine (2012)) states that cessation is the ‘gold
standard’ for the assessment of an MRTP, providing ‘an aspirational
goal for risk and exposure.’ This sets the fundamental objective of an
MRTP: ‘switching to an MRTP must reduce the risk of developing
smoking-related diseases with a risk proﬁle approaching that of
cessation’ (Fig. 4, orange lines). This MRTP assessment framework
lays out the foundations for the assessment approach. In brief, if the
changes observed in adult smokers who switch from cigarettes to
an MRTP consistently approach the changes observed following
smoking cessation, and those changes are further supported by
coherent ﬁndings from non-clinical research, it is reasonable to
conclude that the product will reduce risk.
Smoking-related diseases have a complex etiology. Broadly
accepted mechanisms underlying many smoking-related diseases
are related to impaired organ function from progression of patho-
logical changes and comorbidity. Exposure to cigarette smoke in-
duces molecular changes in the exposed organism and disrupts
various biological processes. This in turn causes alterations at the
cell and tissue level that result in physiological changes that
eventually manifest themselves as diseases (Fig. 5).
Recent advances in molecular measurement and imaging tech-
nologies, mathematical modeling, and computational biology
enable the integrative analysis of large data sets to quantify the
biological impact of exposure to toxicants (Hoeng et al., 2012, 2014;
Sturla et al., 2014). The integration of these methods with standard
toxicological endpoints deﬁnes our systems toxicology-informed
risk assessment approach. Using computable biological network
models (Boue et al., 2015) of the key mechanisms affected by tox-
icants, systems toxicology enables the quantiﬁcation of the bio-
logical network perturbation amplitudes (NPA) (Martin et al., 2012)
caused by exposure to such toxicants and their numerical aggre-
gation into an overall biological impact factor (BIF) (Thomson et al.,
2013). This approach permits a systematic and quantitative
mechanism-based comparison of the biological impact of switching
to a candidate MRTP with continued smoking of CC as well as the
Fig. 5. Chronic exposure to cigarette smoke affects a number of biological networks associated with smoking-related diseases in a causal chain of events known as Adverse
Outcome Pathways (Sturla et al., 2014 and references therein).
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cessation in animal models of disease. We can therefore emulate
disease progression and reversibility in a short timeframe.3.2. The MRTP assessment program
We have developed a generally applicable assessment program
which integrates seven assessment steps (Fig. 6) necessary to
demonstrate that a candidate MRTP i) signiﬁcantly reduces harm
and the risk of tobacco-related disease to individual tobacco users,
and ii) beneﬁts the health of the population as a whole, taking into
account both users of tobacco products and persons who do not
currently use tobacco products. These assessment steps are
designed to provide ﬁve levels of evidence as the assessment pro-
gram is completed (Fig. 6):
1. The ﬁrst step of the assessment is designed to ensure that the
product is manufactured to appropriate quality standards and is
sufﬁciently characterized to document product performance
parameters. This product characterization enables the estab-
lishment of a product speciﬁcation. All products entering the
subsequent assessment steps must meet the established speci-
ﬁcation, as must the products that are introduced to the market.
To ensure this consistency, a well-controlled ChangeFig. 6. The MRTP assessment program. Seven steps of assessment lead to ﬁve levels of
evidence. Taken together, these levels of evidence provide the scientiﬁc evidence to
demonstrate that a candidate MRTP is indeed a reduced risk product.Management process has been established. This process ensures
that the established speciﬁcations are met for any proposed
change to the product before it is implemented by determining
any potential impact on product performance and aerosol
composition. For instance, this process was utilized following
changes to the tobacco blends used in the tobacco stick based on
feedback from taste panels and to ensure sustainability of to-
bacco sources used to formulate the blend. The aerosol gener-
ated from tobacco sticks reformulated with different tobacco
blends (with blend code D2 for the regular version and D1 for
the menthol version) was compared with the aerosol from to-
bacco sticks using the previous tobacco blends (blend code FR1).
There was no change in HPHC yields or in vitro toxicology
ﬁndings for the different blends e further details provided in:
(Schaller et al., 2016b).
2. The second assessment step is designed to analyze the chemical
composition of the aerosol generated by the candidate MRTP
and quantify the reduction in HPHCs formation in comparison
with a cigarette. This analysis is also needed to evaluatewhether
new potentially harmful constituents are generated by the
MRTP. During this step, it is also necessary to assess the inﬂu-
ence of usage patterns and pufﬁng regimens on aerosol compo-
sition, to ensure that the candidate MRTP delivers a stable
reduction in HPHCs, as designed. Furthermore, the analysis of
the aerosol chemistry data, collected under various conditions,
including in the absence of oxygen, conﬁrms the absence of the
involvement of combustion in aerosol generation. The aerosol
particles are also analyzed to verify i) that the aerosol contains a
similar particle size distributions as the one found in CC smoke,
to ensure a similar delivery of nicotine in the aerosol and ii) the
signiﬁcant reduction or absence of the insoluble solid particles
found in cigarette smoke. Finally, during this step we also
analyze the effects of MRTP use on indoor air chemistry to
evaluate its impact on air quality in comparison with CC use
(Mitova et al., 2016) and benchmark against national and in-
ternational standards for exposure to environmental toxicants
e.g.(European Agency for Safety and Health at Work, 2006).
These environmental studies are conducted under well-
controlled and realistic conditions based on accepted building
standards (European Committee for Standardization, 2006).
3. The third step of the assessment determines whether the
reduced formation of HPHCs leads to reduced toxicity in laboratory
models. This step also contributes to the evaluation of any new
hazards. This second level of evidence is based on toxicological
studies conducted both in vitro and in vivo. First, we selected a
battery of in vitro assays designed to assess the cytotoxicity and
the genotoxicity of candidate MRTP aerosols in comparisonwith
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toxicity of candidate MRTP aerosols is analyzed in animal
inhalation studies according to the guidelines from the Orga-
nization for Economic Cooperation and Development
(Organization for Economic Co-operation and Development
(OECD), 2009; Oviedo et al., 2016; Wong et al., 2016). In these
studies we rigorously monitor the test atmosphere composition
and measure biomarkers of exposure in the urine and blood of
the exposed animals. This methodology allows us to assess the
degree of reduced exposure in laboratory models, which provides
an indication of what can be achieved independent of human
behavior and use patterns. This evidence level also provides
support to the substantiation of reduced exposure and risk.
4. The fourth assessment step is used to determine whether
reduced formation of HPHCs and reduced toxicity in laboratory
models lead to reduced risk in laboratory models. This evidence is
based on systems toxicology studies (Sturla et al., 2014) con-
ducted both in vitro and in vivo. The approach adopted for these
in vitro assays is to use primary human cells and organotypic
tissue cultures of human origin, as they are deemed to be more
relevant than immortalized cell lines (Iskandar et al., 2016). The
initial step in this assessment compares the effects of MRTP
aerosol and CC smoke extracts on primary normal human
bronchial epithelial cells using high-content screening
(Marescotti et al., 2016) as well as a detailed mechanistic anal-
ysis of the changes occurring at the transcriptome level
(Gonzalez-Suarez et al., 2014; Kogel et al., 2015). This type of
study provides an initial assessment of an MRTP's impact on key
pathways of toxicity. Second, we assess the impact of the whole
MRTP aerosol in comparison with whole cigarette smoke on
disease mechanisms using in vitro assay systems designed to
recapitulate the structure of the human epithelial tissues
exposed to aerosol/smoke (Kuehn et al., 2015; Mathis et al.,
2013; Schlage et al., 2014; Talikka et al., 2014) and/or key
events in disease pathways (Poussin et al., 2014, 2015; van der
Toorn et al., 2015a). Third, we have complemented in vivo
studies conducted under OECD guidelines (Kogel et al., 2014;
Phillips et al., 2015a) with systems toxicology methods to
quantify the impact of candidate MRTP aerosols on biological
mechanisms perturbed by CC smoke, in conjunction with the
physiological and toxicological endpoints measured under the
OECD guidelines. Fourth, we employ animal models of disease
with a study design that mimics the MRTP Assessment Frame-
work. Brieﬂy, these studies allow us to compare the effects of
initial exposure to CC smoke followed by switching to a candi-
date MRTP aerosol with those caused by continuous exposure to
CC smoke and benchmark them against those of cessation
(Ansari et al., 2016; Phillips et al., 2015b). To enable a compre-
hensive analysis of these effects, these studies leverage the
principles of systems toxicology through a very broad array of
measurements, ranging from comprehensive molecular quan-
tiﬁcations through transcriptomics, proteomics, and lipidomics,
to full histopathological evaluation and disease risk markers,
such as measurement of lung emphysema and atherosclerotic
plaque formation. Furthermore, the use of an animal model such
as the Apoe-/- mouse enables the concomitant analysis and
quantiﬁcation of both pulmonary and vascular effects of smok-
ing, cessation and switching (Boue et al., 2013; Lietz et al., 2013;
Lo Sasso et al., 2016a). Similarly, life-time exposure studies in
the A/J mouse enable the concomitant analysis and quantiﬁca-
tion of both emphysema and cancer-related endpoints (Stinn
et al., 2013) while leveraging the systems toxicology approach.
Studies conducted in this assessment step provide the evidence
that a candidate MRTP presents a reduced risk in laboratory
models. It is essential to establish the performance of theproduct in laboratory models prior to performing clinical
studies.
5. The ﬁfth step of the assessment utilizes clinical studies to assess
whether reduced formation of HPHCs leads to reduced exposure
and risk in humans who use the candidate MRTP. These studies
are conducted with adult smokers who are randomized into
three groups reﬂecting the MRTP Assessment Framework: i)
continued smoking, ii) cessation, or iii) switching to the candi-
date MRTP. Studies conducted in clinical conﬁnement for aweek
can be used to quantify the maximum possible reduction in
HPHC exposure compared with ongoing smoking and cessation,
examples of these studies on a previous product are provided:
(Tricker et al., 2012a, 2012b, 2012c, 2012d). This type of study is
then complemented with studies conducted in ambulatory
mode e.g. (Martin et al., 2012), to assess whether the reductions
in HPHC exposure observed in short-term conﬁnement can be
sustained for a longer period in a near to real-world setting.
Furthermore, with study periods ranging from three months to
one year, it is possible to assess whether reduced exposure leads
to a favorable change in smoking-related clinical risk endpoints,
and hence provide assurance that reduced exposure leads to
reduced risk. The endpoints to assess reduced exposure must be
selected to reﬂect the range of molecular entities contained in
CC smoke for which appropriate biomarkers of exposure can be
reliablymeasured. Similarly, the endpoints to assess reduced risk
must be selected to reﬂect the effects of CC smoke on different
organ systems and biological mechanisms. These disease risk
markers, or biomarkers of effect, must also be responsive to
smoking cessation within the duration of the study and
measurable using validated methods.
As outlined in the introduction (Fig. 1), for effective harm
reduction at the population level, an alternative tobacco product
must not only be scientiﬁcally substantiated to reduce risk, but
also be acceptable to cigarette consumers. It is unlikely that new
products that do not satisfy smokers will enable them to switch.
The nicotine delivery proﬁle and the rewarding subjective ef-
fects of tobacco products are critical components of product
satisfaction and their actual use. Lack of adoption of alternative
nicotine delivery systemsmay therefore be related to ineffective
nicotine delivery and/or a low level of satisfaction. To assess
whether a candidate MRTP delivers satisfying levels of nicotine,
with a delivery proﬁle similar to cigarettes, we also conduct
pharmacokinetic studies in the ﬁfth step of our assessment
program. These studies are conducted along the lines of a pre-
vious report (Picavet et al., 2016).
6. It is important that accurate, non-misleading, scientiﬁcally
substantiated product information and beneﬁts are communi-
cated to adult smokers to provide them with an incentive to
switch from cigarettes to an MRTP. The sixth step of the
assessment involves studies that measure, prior to market
introduction, the likely effect of introducing a new tobacco
product with its associated communication materials on to-
bacco use behavior among adult smokers and non-smokers. This
step assesses the likelihood that adult smokers will switch from
cigarettes to an MRTP, and that former smokers, smokers who
are motivated to quit, and non-smokers are not likely to use the
product. Integral to the above is the assessment of consumer
understanding and risk perceptions that any product commu-
nication would generate. The objective is to ensure that the
intended product communication enables the public to
correctly comprehend the modiﬁed exposure/risk claims and
form the correct perception of the health risks of using an MRTP
in comparison with cigarettes, nicotine replacement therapies,
and cessation.
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conduct post-market studies and surveillance to understand
how the product is used in real-world settings. Passive sur-
veillance measures are used to gather spontaneous reports of
any adverse events related to product use. Longer-term assess-
ment of exposure and health outcomes will be carried out,
together with an ongoing assessment of consumer perception
and tobacco use behavior.
To be effective, an MRTP must beneﬁt the health of the popu-
lation as a whole, accounting for current, former, and never-
smokers (Family Smoking Prevention and Tobacco Control Act;
Food and Drug Administration, 2012). However, population-level
data regarding the risks and uptake of an MRTP prior to its mar-
ket introduction are clearly lacking. To gain an understanding of the
potential impact of an MRTP market introduction on population-
level mortality, one can employ a mathematical model (Vugrin
et al., 2015). Towards this end, PMI has developed a population
health impactmodel (PHIM) for MRTPs (Weitkunat et al., 2015) that
leverages publicly available epidemiology data. PMI's PHIM is
designed to estimate the impact of the introduction of an MRTP on
mortality based on assumptions about the fractional residual risk of
an MRTP relative to that of cigarettes, and possible scenarios for the
uptake of the MRTP in the population. The model estimates the
impact on mortality in a population that survives until a speciﬁc
time after the introduction of the MRTP on the market. Such a
model can be used to predict the potential impact from the intro-
duction of an MRTP based on the exploration of a wide range of
scenarios describing realistically the prevalence of cigarette and
MRTP use, individually and in combination.
The publications in this series are outlined below and report the
results obtained having completed part of the overall assessment
approach with the candidate MRTP THS2.2 in the context of the
second to the ﬁfth step of the MRTP assessment program.
4. Outline of the publications that follow in this series
4.1. Publications of studies conducted in the 2nd step of the MRTP
assessment program
In Part 2 of this series of papers (Schaller et al., 2016a), the
mainstream aerosol composition of both regular and mentholated
THS2.2 is compared with that of the mainstream smoke from a
reference cigarette (3R4F). The criteria for selection and the results
for 58 HPHCs and analytes determined are provided and demon-
strate that the majority of HPHCs measured in THS2.2 aerosol are
reduced by more than 90% when compared with reference ciga-
rette smoke. In vitro toxicological assessment of THS2.2 aerosol
fractions is also described, revealing a >90% reduction in cytotox-
icity, as determined by the neutral red uptake (NRU) assay, and a
similar reduction in mutagenic potency in the mouse lymphoma
assay (MLA). The THS2.2 aerosol fraction was not mutagenic in the
Ames mutagenicity assay.
The performance of THS2.2 operated under simulated extreme
climatic conditions (desert and tropical conditions) was assessed by
monitoring aerosol composition to show no signiﬁcant modiﬁca-
tion with climatic condition. The aerosol composition was also
measured when using pufﬁng regimens that were more intense
than the standard Health Canada Intense (HCI) conditions, to
conﬁrm that HPHC levels remained lower than the levels formed in
reference cigarette smoke generated with the HCI regimen.
In part 3 of this series of papers (Schaller et al., 2016b), the in-
ﬂuence of 43 different tobacco blends (from a large range of tobacco
types) on the formation of HPHCs in THS2.2 aerosol was deter-
mined. The aerosols produced by these blends in the THS2.2contained signiﬁcantly lower concentrations of HPHCs than did
3R4F mainstream smoke. For most HPHCs, the blend composition
had a minimal impact on the yields in the resulting aerosols.
However, some HPHCs presented signiﬁcant variability across the
different blends, likely resulting from the distillation of endogenous
preformed compounds present in certain tobacco types. This
approach provided the information required to intelligently blend
tobaccos to meet consumer needs while maintaining low HPHC
delivery.
4.2. Publications of studies conducted in the 3rd and 4th step of the
MRTP assessment program
In part 4 of this series of papers (Wong et al., 2016), a 90-day
nose-only inhalation study in rats was performed according to
OECD Test Guideline 413 (Organization for Economic Co-operation
and Development (OECD), 2009). The approach was modiﬁed to
combine classical and systems toxicology approaches, tran-
scriptomic analysis and miRNA expression (the latter results
included in part 5 below). The effects of exposure of respiratory
tract organs in THS2.2-exposed animals were much lower than
those in rats exposed to 3R4F cigarette smoke. The results also
conﬁrmed that for the THS2.2 aerosol, there was no apparent new
toxicity effects, compared with 3R4F cigarette smoke.
Part 5 of this series of papers (Sewer et al., 2016) demonstrated
that 3R4F cigarette smoke, but not THS2.2 aerosol, caused global
miRNA downregulation. Certain miRNA species, notably those
associated with the inﬂammatory response, were upregulated in
3R4F cigarette smoke-exposed lung, but reduced following THS2.2
aerosol exposure. This work contributed to an increase in mecha-
nistic understanding of the complex exposure responses.
In part 6 of this series of papers (Oviedo et al., 2016), a 90-day
nose-only inhalation study in rats was performed according to
OECD Test Guidelines 413 (OECD, 2009) on amentholated variant of
THS2.2 (THS2.2M) assessing both classical endpoints (described in
the OECD guidelines such as histopathology, etc.), and com-
plemented with transcriptomics and quantitative proteomics ana-
lyses of respiratory nasal epithelium and lung tissue, together with
lipidomic analysis of lung tissue. Rats were exposed to either
ﬁltered air (sham), THS2.2M, two mentholated reference cigarettes
(MRC, designed to meet 3R4F speciﬁcations with menthol added at
different levels), or the 3R4F reference cigarette. The study results
show that systemic toxicity and alterations in the respiratory tract
were signiﬁcantly lower in THS2.2M-exposed rats than in MRC and
3R4F.
In part 7 of this series of papers (Kogel et al., 2016), the systems
toxicological assessment results from the study described in part 6
are discussed. The results demonstrated adaptive responses in the
respiratory nasal epithelium to 3R4F cigarette smoke; these adap-
tations included squamous cell metaplasia and inﬂammatory
response, with a close correspondence of the molecular and his-
topathological ﬁndings. In contrast, the adaptive tissue and mo-
lecular changes to THS2.2M aerosol exposure were much weaker,
and limited mostly to the highest THS2.2M concentration in female
rats. 3R4F smoke exposure induced an inﬂammatory response,
triggered cellular stress responses, and affected sphingolipid
metabolism. These responses were not observed or were much
lower after THS2.2M aerosol exposure.
4.3. Publications of studies conducted in the 5th step of the MRTP
assessment program
Part 8 of this series of papers (Haziza et al., 2016) describes a 5-
day, controlled, parallel group, open-label clinical study where 160
smoking, healthy adult subjects were randomized to three groups
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ipants), (2) continue to use their own non-menthol CC brand (CC
group, 41 participants), or (3) to refrain from smoking (Smoking
abstinence [SA] group, 39 participants). All biomarkers of HPHC
exposure, except those associated with nicotine exposure, were
signiﬁcantly reduced in the THS group compared with the CC
group, and approached the levels observed in the SA group. Greater
product consumption and total puff volume were reported in the
THS group, but exposure to nicotine was similar to CC at the end of
the conﬁnement period in the clinic. Reduction in the urge to
smoke was comparable between the THS and CC groups, and the
THS was well tolerated with few adverse events.
Part 9 of this series of papers (Martin et al., 2016) reports the
results from gene expression proﬁling of whole blood collected
during the clinical study referred to in part 8 (Haziza et al., 2016). A
whole-blood-derived gene signature that can distinguish smokers
from either non-smokers or former smokers with a high degree of
speciﬁcity and sensitivity has been described previously (Martin
et al., 2015). The small signature, consisting of only 11 genes, was
tested on the blood transcriptome of subjects enrolled in the clin-
ical study as a complementary measure of exposure response. The
signature performed remarkably well in predicting signiﬁcant
reduction in exposure response within just 5 days after subjects
switched to THS2.2 or abstained from smoking. The blood tran-
scriptomics proﬁling can therefore serve as a complementary
measure of exposure response.
5. Conclusions
The data presented in this series of papers demonstrates that,
compared with the 3R4F reference cigarette, both regular and
mentholated versions of THS2.2 yield signiﬁcantly reduced levels of
HPHCs. This reduced formation of HPHCs by both versions of
THS2.2 leads to a reduced toxicity, assessed both in vitro using as-
says for cytotoxicity and mutagenicity and in vivo in two distinct
90-day inhalation studies in rats. An important ﬁnding is that the
reduced formation of HPHCs (measured under standardized ma-
chine smoking conditions) also leads to the reduced exposurewhen
used ad libitum in a short-term clinical study conducted in adult
smokers in a controlled environment.
We have previously reported on a systems toxicology study
(step four of the MRTP assessment program) conducted in an ani-
mal model assessing the impact of THS2.2 on disease mechanisms
(Lo Sasso et al., 2016b; Phillips et al., 2016; Titz et al., 2016). This
study has shown that exposure to THS2.2, in comparisonwith 3R4F
exposure, leads to a reduced exposure to HPHCs, which in turn
leads to a reduced perturbation amplitude of disease-associated
mechanisms as well as a reduced severity of disease endpoints
in vivo. In addition, the effects of switching from 3R4F to THS2.2
were approaching those of cessation. Furthermore, we have pre-
viously reported on ﬁve in vitro systems toxicology studies con-
ducted with THS2.2 in human primary cells. These studies were
designed to compare the effects of 3R4F smoke with those of
THS2.2 aerosol on key cellular toxicity endpoints (Gonzalez-Suarez
et al., 2016), organotypic airway epithelium (Iskander et al., 2016b;
Zanetti et al., 2016), as well as on mechanisms involved in vascular
inﬂammation (Poussin et al., 2016)and endothelial dysfunction
(van der Toorn et al., 2015b). The results of these studies showed
that THS2.2 aerosol is less toxic than 3R4F smoke. Taken together,
all these results show that THS2.2 has the potential to be an MRTP.
6. Outlook
The data presented in this series of papers and the previously
published studies (Poussin et al., 2016; van der Toorn et al., 2015b;Gonzalez-Suarez et al., 2016; Phillips et al., 2016; Titz et al., 2016; Lo
Sasso et al., 2016b; Iskandar et al., 2016b; Zanetti et al., 2016) are an
essential component of our MRTP assessment program applied to
THS2.2. The converging lines of evidence emerging from these
study results show that THS2.2 has the potential to be a reduced-
risk product. However, to conﬁrm that THS2.2 is indeed a
reduced-risk product we are conducting longer-term clinical
studies, designed to quantify disease risk markers in addition to
biomarkers of exposure. Future publications describing in more
details the absence of combustion during THS2.2 use (i.e. that the
aerosol produced is not smoke), further clinical studies, perception
and behavior studies, and population impact modeling will be
published elsewhere.
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